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1. Introduction 
Identification of the physiological roles and elucidation of the molecular mechanisms 
involving tumor suppressor genes and their gene products are important for a more 
comprehensive understanding of cancer pathogenesis. Since the Knudson’s statistical 
studies on retinoblastoma, neuroblastoma, and pheochromocytoma, which led to the 
conclusion that the occurrence of these tumors fits a two-mutation model (Knudson, 1971; 
Knudson & Strong, 1972), it became recognized that there were some genes that function to 
inhibit tumor development. The model stated that tumorigenesis results when there are 
genetic alterations such as deletions and mutations in both alleles of a gene in a cell 
(Knudson, 1971; Knudson & Strong, 1972). A tumor suppressor gene may have one or more 
functions related to cell division and differentiation, extracellular communication, tissue 
formation or senescence (Hollingsworth & Lee, 1991).  
Several regions of the human chromosome 3 have been identified as susceptible sites for 
homozygous deletions and mutations that may lead to inactivation of one or more tumor 
suppressor genes. A particular tumor suppressor gene candidate 101F6 is located within a 
narrow 630-kb region on chromosome 3p.21.3, called LUCA (lung cancer region) (Lerman & 
Minna, 2000; Zabarovsky et al., 2002). Interestingly, the 101F6 protein is expressed in normal 
lung bronchial epithelial cells and fibroblasts but is lost in most lung cancers (Ohtani et al., 
2007). Previous studies have shown that forced expression of the 101F6 gene via adenoviral 
vector-mediated gene transfer (Ji et al., 2002) or via nanoparticle injection (Ohtani et al., 
2007) caused the inhibition of tumor growth in non-small cell lung cancer cells in vitro and in 
vivo. The treated cancer cells were also found to accumulate ascorbate (AsA) when 
incubated in a medium containing AsA (Ohtani et al., 2007). Apoptosis and autophagy of 
the cancer cells were reportedly to be enhanced by the treatment and were postulated to be 
caused by the synergistic action of the 101F6 gene and AsA though the mechanism of the 
action is still not clear (Ohtani et al., 2007). 
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The human 101F6 gene was found to encode a protein consisting of 222 amino acids and 
was predicted to be a member of the cytochrome b561 protein family (Tsubaki et al., 2005). 
Proteins such as adrenal cytochrome b561 (Tsubaki et al., 1997), duodenal cytochrome b561 
(Mckie et al., 2001), and stromal cell-derived receptor 2 (Vargas et al., 2003) that were 
classified under this family have a common “b561 core domain” consisting of four 
transmembrane -helices that have four totally conserved His residues for the binding of 
two heme b groups (Okuyama et al., 1998; Tsubaki et al., 2005). The adrenal cytochrome b561, 
as a classic representative of this family, is a highly hydrophobic protein, consisting of six 
transmembrane -helices with a molecular mass of 28 kDa and is located in the secretory 
vesicle membranes of adrenal chromaffin cells. This protein is involved in a transmembrane 
electron transfer reaction from cytosolic AsA to intravesicular monodehydroascorbate 
(MDA) radical that replenishes reducing equivalents to maintain physiological levels of AsA 
inside the vesicles (Kobayashi et al., 1998; Seike et al., 2003). AsA is an essential water-
soluble vitamin that maintains the activity of copper-containing enzymes such as dopamine 
-hydroxylase and peptidylglycine -amidating monooxygenase by providing electrons to 
the copper center of the enzyme (Prigge et al., 2000) and to keep the intravesicular side in 
reduced state to protect otherwise very labile catecholamines. For efficient electron transfer, 
adrenal cytochrome b561 contain a putative AsA-binding motif on the cytosolic side close to 
the cytosolic heme center and a putative MDA-radical binding motif on the intravesicular 
side close to the intravesicular heme center, respectively (Okuyama et al., 1998). Such motifs 
were found to be conserved in other subfamilies of cytochrome b561, including duodenal 
cytochrome b561 and plant cytochrome b561 (Tsubaki et al., 2005). 
Comparative analysis on the amino acid sequences of seven subfamilies of the cytochrome b561 
protein family showed that 101F6 protein does not contain the MDA-radical binding motif 
while the AsA-binding motif was significantly modified (“modified motif 1”) (Tsubaki et al., 
2005). These results suggested that redox active biofactor(s) other than AsA or MDA radical 
might be responsible as redox mediators of the 101F6 protein (Tsubaki et al., 2005). It is very 
intriguing to consider that the 101F6 protein has a role for transmembrane redox signal 
transduction via this unknown redox-linked activity. Therefore, the “modified motif 1” may be 
a primary candidate for conducting such transmembrane redox reactions (Tsubaki et al., 2005). 
Thus, clarification of the properties and three-dimensional structure of the 101F6 protein is 
highly necessary in understanding the role of this transmembrane protein as a tumor 
suppressor and as a controlling factor in human lung cancer development. 
Although the cytochrome b561 protein family has a large numbers of its members (human 
tissues contain 6 members), none of them has ever been successfully crystallized for analysis 
by X-ray diffraction. Though we have attempted the crystallization for various members of 
the cytochrome b561 family, we have been limited by the amount of samples for more 
extensive screenings. A major barrier to crystallizing membrane proteins from higher 
eukaryotes (animals and plants) is the inability to purify sufficient amounts of non-
denatured active proteins for conducting the crystallization trials. Indeed, except for the 
classic cytochrome b561 protein from bovine adrenal chromaffin vesicles, purification of 
cytochrome b561 from native tissues has been found to be almost impossible. Further, 
heterologous expression systems for the membrane protein including the members of the 
cytochrome b561 family, by employing the prokaryote Escherichia coli, the yeast Saccharomyces 
cerevisiae, the insect Sf9 cells, and mammalian cells, showed  limited success based on the 
evaluation of their final qualities and/or quantities. Recently, the methylotrophic yeast, 
Pichia pastoris, has proven to be a very useful system to express and purify milligram 
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quantities of membrane proteins (Abramson et al., 2003; Huang et al., 2003; Jiang et al., 
2003). However, instances about its use as a host for the expression of mammalian 
membrane proteins was limited (Long et al., 2005). 
We have previously reported about the functional expression, purification and 
characterization of recombinant human 101F6 protein, which was expressed as a poly-
histidine tagged protein in methylotrophic yeast Pichia pastoris (Recuenco et al., 2009). The 
purified 101F6 protein exhibited characteristic properties as a member of the cytochrome b561 
protein family, particularly with regards to spectral characteristics and electron transfer 
activities with AsA and MDA radical. In this paper, we want to present our optimized 
protocol for the human 101F6 protein expression and purification. Further, we have 
succeeded in the crystallization of recombinant human 101F6 protein for the first time. We 
also present preliminary results on the quality of the human 101F6 protein crystals. 
2. Materials and methods 
2.1 The Pichia pastoris expression system 
In our present study, we employed the Pichia pastoris expression system (Pichia pastoris GS115 
cells and a pPICZB vector; from Invitrogen Corp., Tokyo, Japan) for the successful expression 
of human 101F6 gene. As a single-celled microorganism, yeast Pichia pastoris is easy to 
manipulate and is, therefore, very suitable for culture. However, it is a eukaryote and capable 
of many of post-translation modifications onto the heterologously expressed proteins such as 
proteolytic processing, folding, disufide bond formation, and glycosylation, which are 
performed by higher eukaryotic cells. Most importantly, Pichia pastoris cell is a very suitable 
host for the expression of membrane proteins, particularly for integral membrane proteins, 
because of its eukaryotic nature (e.g., presence of membranes within the cytosolic milieu).  
It was proposed that, compared to insect cells (e.g., Sf9 cell) or other mammalian cultured 
cells, Pichia pastoris cells are much easier to handle, can be grown at lower cost, and can be 
expressed quicker in a large scale (Asada et al., 2011). Such successful examples for 
expressing eukaryotic membrane proteins were reported previously (Weiß et al., 1998; 
Wetterholm et al., 2008; Nakanishi et al., 2009a; Nakanishi et al., 2009b; Alisio & Mueckler, 
2010; Ostuni et al., 2010; Mizutani et al., 2011).  
2.2 Construction of the expression plasmid pPICZB-101F6-His8 
Procedure for a molecular cloning of the human 101F6 gene was described previously 
(Recuenco et al., 2009). Construction of the expression plasmid, pPICZB-101F6-His8, was 
described previously (Recuenco et al., 2009). Briefly, the thrombin-specific sequence 
followed by the eight-histidine residue-tag (QPSALVPRGSSAHHHHHHHH; the underline 
indicates the thrombin-specific sequence) was introduced at the C-terminus of human 101F6 
protein, resulting in a total of 240 aa residue-long with a molecular mass of 25996.9 Da. An 
eight-histidine residue-tag sequence, instead of a usual six-histidine residue-tag, was added 
to provide a stronger binding affinity towards Ni-NTA affinity column. Such a poly-
histidine-residue tag was employed for the expression of mammalian glucose transporter 
(eight-histidine residue) (Alisio & Mueckler, 2010) and G-protein coupled receptors (deca-
histidine residue) (Yurugi-Kobayashi et al., 2009). Introduction of the tag-sequences at the C-
terminus of human 101F6 protein was chosen with considerations about the increase in 
length of the C-terminal part and its successful protein expression in the ER membranes of 
Pichia pastoris cells. 
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2.3 Expression and purification of the human wild-type 101F6 protein 
The pPICZB-101F6-His8 plasmids obtained from the transformed E. coli cells were purified 
and linearized using Pme I and were used for the transformation of Pichia pastoris GS115 
competent cells according to EasyCompTM transformation protocol (Invitrogen Corp., 
Tokyo, Japan). Selection was done by plating onto YPDS medium containing 400 µg/mL 
Zeocin (Invitrogen Corp., Tokyo, Japan), a bleomycin-like compound that kills cells by 
introducing lethal double-strand breaks in chromosomal DNA. In our screening process, the 
concentration of Zeocin was increased four times higher than the recommended 
concentration of 100 µg/mL, to obtain Zeocin hyper-resistant transformants that would 
have multicopy clones. The Zeocin-resistant protein (the product of the Sh ble gene in the 
pPICZB vector) confers resistance to the transformed cells stoichiometrically, not 
enzymatically, by binding to and inactivating the drug. Therefore, such transformants may 
ultimately result in an increase in the level of heterologous 101F6-His8 protein production 
(Romanos et al., 1998).  
Single colonies with a hyper Zeocin-resistant activity from the YPDS-Zeocin plates were 
inoculated into 1000-mL Erlenmeyer flasks with a baffled bottom containing 250 mL BMGY 
media (2% glycerol). During the usual induction procedure of such transformants by the 
addition of methanol (final 2%) as described previously (Recuenco et al., 2009), the color of 
the medium become reddish, indicating a successful expression of a holo-form of the 101F6 
protein in the Pichia pastoris cells. After harvesting the induced cells, microsomal fractions 
were prepared in the presence of protease inhibitor cocktail (Protease Inhibitor Cocktail for 
General Use (100X); Nacalai Tesque, Kyoto, Japan). Then, the cytochrome b561 content based 
on the absorption at 561 nm was calculated. Typical results showed a total yield of 600~1000 
nmoles of cytochrome b561 in microsomal fraction obtained from a 250-mL culture after 96 h 
of incubation (Table 1). 
Solubilization of microsomal membrane fraction was conducted with -octyl glucoside 
(2%)(Anatrace, Maumee, Ohio, USA). All the following steps were conducted at 4°C or on 
ice to avoid the formation of aggregates. Further, to obtain a better yield, we skipped the 
step of DEAE-Sepharose column chromatography, which was included in the original 
purification procedure (Recuenco et al., 2009). Thus, the solubilized membrane proteins 
from the microsomal fraction were directly applied to a pre-packed Ni-NTA-Sepharose (GE 
Healthcare Japan. Tokyo, Japan) column equilibrated with a buffer containing 300 mM NaCl 
and 10 mM imidazole. Removal of interfering proteins was achieved by washing the column 
with the buffers containing 20 mM imidazole and 50 mM imidazole. Then, the 101F6-His8 
protein was eluted with the buffer containing 300 mM imidazole. The purified sample was 
promptly desalted with PD-10 column (GE Healthcare Japan, Tokyo, Japan) equilibrated 
with 50 mM phosphate buffer containing 1 % -octyl glucoside and 10 % glycerol.  
3. Results 
3.1 Properties of the purified 101F6-His8 protein 
Table 1 shows a typical example for the protein yield and the cytochrome b561 content at all 
the purification steps. From a 250-mL culture, which provides about 16-20 grams of wet cell 
bodies expressing the 101F6-His8 protein with an approximate cytochrome b561 content of 
800~900 nmoles, it was possible to purify about 0.60 mg of the recombinant human 101F6-
His8 protein with the cytochrome b561 content of 180 nmoles, with a purification fold of 56 
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from the stage of microsomes to the stage of the final desalting. Since the cytochrome b561 
content at the stage of microsomes would include a considerable amount of other b-type 
cytochromes, such as cytochrome bc1 complex, the actual yield of the recombinant 101F6-
His8 protein would be much better. Then, the purified 101F6-His8 protein was evaluated by 
SDS-PAGE, visible absorption spectroscopy, MALDI-TOF mass spectrometory, redox 
titration, heme content analysis, in comparison with those of classic chromaffin granule 
(CG) (i.e., chromaffine vesicle) cytochrome b561.  
SDS-PAGE analysis on the purified 101F6-His8 protein showed a single protein band with 
its estimated molecular weight around 26 kDa. Achievement of the highly purified sample 
by a single column chromatography step as in our present study might be possible by the 
better binding affinity of the 101F6-His8 protein towards Ni-NTA-Sepharose column, by the 
introduction of eight-histidine residue-tag at the C-terminus (Alisio & Mueckler, 2010). 
Occasionally we found a dimer (or trimer) form of the 101F6-His8 protein monomer upon 
the SDS-PAGE analysis. We found that such a formation of the dimer (or trimer) form was 
not due to a disulfide bond formation between the monomers and could be avoided 
without the heat treatment of the purified sample before the analysis. The great tendency 
to form aggregates of the 101F6-His8 protein during the purification steps is likely to be 
related to a spontaneous formation of the dimer (or trimer) and might be the intrinsic 
nature of the cytochrome b561 protein family more or less (Apps et al., 1984; Duong et al., 
1984; Liu et al., 2011). 
Visible absorption spectra of the purified 101F6-His8 protein were analyzed in the region 
from 700 to 340 nm. The purified 101F6-His8 protein exhibited typical spectra characteristics 
as a member of the cytochrome b561 family (Tsubaki et al., 1997). A strong Soret band at 414 
nm and weak Q bands between 500-600 nm were observed for the oxidized form. Addition 
of sodium dithionite produced the fully-reduced form with a Soret band at 427 nm and 
resolved Q bands at 529 (-band) and at 561 nm (-band) (Figure 1). For the heme content 
analysis, the purified 101F6-H8 protein was converted to a pyridine hemochrome by the 
addition of pyridine and NaOH according to the method of (Fuhrhop & Smith, 1975) as 
modified with (Berry & Trumpower, 1987). An extinction coefficient value for heme B 
pyridine hemochrome of 34.4 mM-1cm-1 at 557 nm (in the absolute spectrum) (Fuhrhop & 
Smith, 1975) was used. Protein concentration was determined by a modified Lowry method 
(Markwell et al., 1981) and by the Bradford method (Bradford, 1976). Bovine serum albumin 
was used as a standard in each method. Concentration of the standard solution was 
assessed spectrophotometrically using an extinction coefficient of 6.60 %-1cm-1 at 280 nm. 
The heme content of the purified 101F6-His8 protein was found to be 1.59 (±0.06) mole/mole 
protein, as calculated from the absolute spectrum at 557 nm of the pyridine hemochrome. 
This value was slightly less than the calculated value for bovine CG cytochrome b561 at 1.70 
mole heme/mole protein (Tsubaki et al., 1997). Nevertheless, the value supported the 
presence of two heme B groups per protein in the purified sample, like the classic CG 
cytochrome b561. This result was also consistent with the result of EPR analysis on the 
purified form of oxidized 101F6-His8 (Recuenco et al., unpublished), which showed the 
presence of two independent heme centers. 
Mass spectrometric analyses were conducted with a Voyager DE Pro mass spectrometer 
(Applied Biosystems, Foster City, California, USA). The estimated molecular mass of the 
intact 101F6-His8 was found as 25941.70 Da, very close to the theoretical value 
corresponding to 1-240 residue (25996.9 Da; average). In total of 240 amino acid residues of 
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the 101F6-His8 protein, we could identify most of the cleaved peptides with coverage of 
more than 99% and there was no post-translational modification occurred. These results 
confirmed the successful expression and purification of the intact 101F6-His8 protein. 
 
 
Purification steps 
Total 
protein 
(mg) 
Total 
cytochrome 
b561 content 
(nmol) 
Specific 
content 
(nmol/mg 
protein) 
Purification 
Fold 
Yield 
(%) 
Microsomes 165.75 861 5.20 1 100 
 
β-octyl glucoside-
solubilized 
 
109.20 
 
459 
 
4.20 
 
0.81 
 
53.3 
 
Ni-NTA 
chromatography/desal/ 
concentrate 
 
 
0.60 
 
 
176 
 
 
293.3 
 
 
56 
 
 
20.5 
Table 1. Purification of recombinant human 101F6-His8 protein (starting from a culture of 
250 mL-scale).  
 
 
Fig. 1. Visible absorption spectra of purified 101F6-H8 protein. Spectra were measured in 
oxidized (solid line), AsA (10 mM)–reduced (broken line), and dithionite-reduced (dashed 
broken line) states with cytochrome b561 content of 1.66 M in 50 mM potassium phosphate 
buffer (pH 7.0) 1.0% -octyl glucoside at room temperature. 
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The 101F6-His8 protein was found to be reducible by AsA very efficiently. Redox titration 
analysis showed that its redox behaviour could be simulated satisfactory by assuming the 
presence of two independent heme b prosthetic groups with their midpoint potentials at 
+89.5 and +13.1 mV, respectively, slightly lower than the corresponding values of bovine 
CG cytochrome b561 (Tsubaki et al., 2000; Takeuchi et al., 2001). Electron accepting activity 
from AsA to the oxidized 101F6-His8 protein and electron donating activity from the 
reduced 101F6-His8 protein to MDA radical were further analyzed by a stopped-flow and 
pulse-radiolysis techniques, respectively. The results showed that these two properties are 
distinct from bovine CG cytochrome b561: (a) very high electron accepting rate constant from 
ascorbate compared to other cytochrome b561 (Kobayashi et al., 1998); (b) absence of initial 
pH-dependency from AsA to the oxidized heme of 101F6-His8 protein (Takigami et al., 
2003). Details were described elsewhere (Recuenco et al., unpublished results). These 
properties may be directly related to the tumor suppressor activity of 101F6-His8 protein in 
human lung tissues. 
3.2 Protein crystallization screening 
Purified eight-histidine-tagged human 101F6 protein in 50 mM potassium phosphate 
buffer (pH 7.0) containing 1% β-octyl glucoside was freed from aggregates by 
centrifugation at 15,000 rpm for 5 minutes. The supernatant containing the solubilized 
protein was put in Amicon Ultra-4 centrifugal filter unit (UFC 801096; Nihon Millipore 
K.K., Tokyo, Japan) and centrifuged at 3,000 rpm to concentrate the protein sample. The 
concentrated sample was again centrifuged to remove aggregates and then filtered 
through a 0.22 μm syringe filter. A 0.3 mL sample with a concentration at least 150 μM of 
cytochrome b561 content was enough for screening approximately 1000 different 
conditions using a crystallization robot, Hydra II Plus One system (Matrix Technologies 
Corp., Thermo Fischer Scientific Inc., Hudson, New Hampshire, USA). Screening of the 
crystallization condition was performed by a sitting-drop vapor diffusion method on 96-
well Intelli-plates at room temperature. A ratio of 0.3 μL protein and 0.3 μL precipitant 
over 30 μL well solution was employed. Crystallization screening solutions such as, 
Classics Neo, Classics Neo II, JCSG+, Mb Class I, MPD, pH clear, pH clear II, AmSO4, PEG 
I, and PEG II Suite (Qiagen K. K., Tokyo, Japan), were used. After the deposition of the 
samples, plates were incubated at 20°C for about 14 days. 
Crystals with size of 0.020 mm were formed from the following precipitants: 
JCSG+ (20 % PEG3350, 0.2 M sodium thiocyanate), Classics Neo (1.0 M imidazole (pH 7.0), 
and Classics II (25 % PEG3350, 0.2 M ammonium acetate, 0.1 M bis-Tris (pH 5.5) (Figure 2). 
Diffraction data were first measured on an R-axis imaging plate (IP) area detector (Rigaku 
Corp., Tokyo, Japan) at the Protein Design Laboratory, Yokohama City University. The X-
ray diffraction data of the crystals were further collected at the Photon Factory in Tsukuba, 
Ibaraki, Japan (Beam line; PF-BL5A). The crystals from Classics II (25 % PEG3350 (w/v), 0.2 
M ammonium acetate, 0.1 M bis-Tris (pH 5.5) were able to produce an X-ray diffraction 
pattern with a maximum resolution at 8.4 Å (Figure 2B). Further, optimization of the 
conditions using 20 % PEG3350 (w/v), 0.2M ammonium acetate, 0.1 M bis-Tris (pH 5.5) and 
15 % PEG3350 (w/v), 0.2 M ammonium acetate, 0.1 M bis-Tris (pH 5.5) produced better 
crystals (Figure 3).  The crystals from 15 % PEG3350 (w/v), 0.2M ammonium acetate, 0.1M 
bis-Tris (pH 5.5) produced a diffraction pattern of spots with the highest resolution at 4 Å 
(Figure not shown).  
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Fig. 2. Screening of crystallization conditions for 101F6-His8 protein. (A-C) Crystals formed 
upon crystallization screening with a sitting-drop vapor diffusion method on 96-well plates. 
Conditions: Precipitant, 25% PEG3350, 0.2M Ammonium acetate, 0.1M bis-Tris (pH5.5) 
solution; Temperature 20 °C; Incubation time 10-14 days; Protein concentration, 150 μM in 
50 mM potassium buffer (pH 7.0) containing 1.0 % β-octyl glucoside. (D-F) Diffraction 
patterns of the 101F6-H8 crystals obtained from the conditions described above. Highest 
resolution at 8 Å was obtained at Tsukuba Photon Factory (Beam Line: PF-BL5A, Exposure 
time=20 sec). 
4. Discussion 
The candidate tumor suppressor protein 101F6 could be an important factor in cell 
proliferation and apoptosis. The reported induction of apoptosis in cultured cancer cells and 
inhibition of tumor growth in mouse models on forced expression of the 101F6 gene (Ji et al., 
2002; Ohtani et al., 2007) gave a promising outlook for cancer prevention and treatment. In 
the present study, the human 101F6 protein was expressed and purified successfully from 
the yeast Pichia pastoris cells. The purified 101F6-His8 protein was found to be reducible by 
AsA very efficiently and can donate electrons to MDA radical very rapidly. These new 
findings provide clues as to the possible role of the 101F6 protein in AsA-recycling that may 
be linked to processes that ultimately lead to apoptosis (Figure 3). Our view is basically 
consistent with the proposal by Ohtani et al., in which the exogenously-expressed 101F6 
protein in cancer cells enhanced intracellular uptake of AsA, leading to an accumulation of 
cytotoxic H2O2 and synergistic killing of tumor cells through caspase-independent apoptotic 
and autophagic pathways (Ohtani et al., 2007). Our present view, however, needs further 
clarification to explain the possible mechanism(s) to enhance the cellular uptake of AsA by 
BA 
FED 
C
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the introduction of the 101F6 protein into the ER membranes. Further, the proximate target 
of the 101F6 protein in the proposed AsA-signaling pathway must be clarified. Importantly, 
in our scheme in Figure 3, H2O2 was not included. Ohtani et al. observed a significant 
increase in the intracellular accumulation of H2O2 in non-small cell lung cancer (NSCLC) 
cells only in response to exogenous 101F6 and AsA (Ohtani et al., 2007). Therefore, it might 
be very important to clarify the molecular mechanism concealed in the 101F6 protein in 
facilitating the formation and accumulation of cytotoxic H2O2 by the increased concentration 
of cytosolic AsA. For these purposes, complete three-dimensional structural information 
about this hydrophobic membrane protein is highly necessary and it would be very helpful 
for the understanding of the mechanism of the putative tumor suppression function and, 
further, in the design of therapeutic agents for cancer.  
 
 
 
 
Fig. 3. Crystals formed from crystallization screening with a sitting-drop vapor diffusion 
method after optimization of precipitant composition. (A and B) 15% PEG3350 (w/v), 0.4M 
Ammonium acetate, 0.1M bis-Tris (pH6.0). Temperature 20°C; Incubation time, 10-14 days; 
Protein concentration, 150μM of 101F6-His8 protein in 50 mM potassium phosphate buffer 
(pH 7.0) containing 1.0 % β-octyl glucoside.  
A
B
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Fig. 4. Proposed topological model and function of the human tumor suppressor 101F6 
protein in human cells. The human 101F6 protein contains six transmembrane -helices and 
two b-type hemes. Alignment with other cytochromes b561 identified four histidine residues 
that might be the axial ligands of two hemes: His48 and His120 for the intravesicular heme; 
and His86 and His159 for the cytosolic side heme. The 101F6 protein may be located in the 
small vesicle or ER membranes. The 101F6 protein may function as an electron transfer 
protein inside the vesicles for AsA recycling. An electron donor donates an electron to the 
cytosolic heme of the 101F6 protein. The electron is then passed to the intravesicular heme 
via intramolecular electron transfer. MDA radical that might have been generated in some 
processes in the lumen accepts the electron from the intravesicular heme to re-generate AsA. 
AsA in the lumen of the vesicles is used as a cofactor to activate a certain target protein that 
may signal a caspase-independent pathway to induce apoptosis or autophagy. 
Purification and crystallization of membrane proteins are considered to be much more difficult 
than soluble proteins. This difficulty is mostly due to the presence of transmembrane domains, 
in which hydrophobic -helical domains were covered with detergent molecules, which was 
inevitably used for the solubilization of the proteins, forming a micelle structure. Such 
hydrophobic domains do not have specific interactions with other protein molecules, having a 
tendency to form non-specific aggregates during the protein purification, therefore, hampered 
the purification of membrane proteins into a homogenous state. Similar problems occur 
during the crystallization of a membrane protein. To obtain successful protein crystals of a 
membrane protein, we may have two strategies; one way is increasing a part of the 
hydrophilic domain to facilitate the specific interactions among the hydrophilic amino acid 
residues of the protein. Usually, a monoclonal body specific to such a hydrophilic domain 
would be used for such purpose. The other way is a choice of detergents. To find the best 
conditions for crystal growth with a suitable crystal group, one needs large amounts of pure 
protein sample and suitable detergents (Gutmann, 2007; Wetterholm et al., 2008). 
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We could obtain enough amounts of nearly homogeneous sample of human 101F6 protein 
in the form of eight-histidine-tagged fusion protein from the heterologous expression 
system of yeast Pichia pastoris cells. The protein samples were subjected to crystallization 
trials where initial screening was performed using a crystallization robot and commercially-
available protein crystallization precipitants containing varying proportions of different 
salts, polymers and organic solvents. This allowed the screening of about 1000 different 
conditions within a very short time and usage of a tiny amount of the protein sample.  
The β-octyl glucoside detergent used throughout in this study was a small micelle-forming 
detergent. Small micelle-forming detergents solubilize membrane proteins efficiently and 
leave hydrophilic parts of the protein being exposed to the water medium, allowing better 
interactions with other protein molecule(s) that are required for the formation of protein 
crystal lattice (Gutmann, 2007). However, if the hydrophobic regions are not well-covered 
with detergent molecules, aggregation of the membrane protein may occur. Large micelle-
forming detergents such as n-dodecyl-β-D-maltoside and polyoxyethylene dodecyl ether 
can be used to address this problem. But with the use of these detergents, only small 
portions of the protein may be actually available for the lattice formation with other protein 
molecules. Thus, the human 101F6 protein should be subjected to a detergent screening to 
obtain better diffracting crystals and resolve its X-ray structure. 
5. Conclusion 
Previous studies showed that forced expression of the 101F6 gene in cultured cancer cells 
and in animal cancer models could significantly inhibit tumor growth. These promising 
results encouraged our investigation on the properties and function of the 101F6 protein. 
The human 101F6 protein was successfully expressed as an octahistidine-tagged fusion 
protein in the methylotropic yeast Pichia pastoris and was purified in its functional form. 
Characterization of the protein revealed that it possesses similar absorption spectra and 
AsA-reducibility as the prototype bovine CG cytochrome b561. However, the results from 
kinetic studies on the reduction by AsA and the oxidation by MDA radical indicated 
different properties in the electron transfer mechanism. Most of the differences may be 
attributed to the low sequence homology of the 101F6 protein to the bovine CG cytochrome 
b561. Other previously studied members of the cytochrome b561 family are much more similar 
to each other because of their higher sequence homology. Present study showed that it was 
possible to produce high quality sample and good diffracting crystals of the octahistidine-
tagged 101F6 protein. An extensive screening for the best condition for crystallization 
should be done with the use of other detergents (such as n-dodecyl-β-D-maltoside), 
precipitants, and monoclonal antibodies. The detailed protein structure of the 101F6 protein 
through X-ray crystallography may be attained in the near future. 
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